Overview

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Forest Laboratories
Treatments:
Angiotensin II
Angiotensinogen
Giapreza
Metoprolol
Nebivolol
Polystyrene sulfonic acid
Criteria
Inclusion Criteria:

- Stage I hypertension (140-159/90-99 mmHg)

- Men and women age 18-65

Exclusion Criteria:

- Congestive heart failure or coronary artery disease

- Blood pressure averaging >159/99 mmHg or resting heart rate < 55 bpm

- Serum creatinine > 1.4 mg/dL

- Asthma or chronic obstructive pulmonary diseases

- Left ventricular hypertrophy by echocardiography or ECG

- Pregnancy

- Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin

- Any history of substance abuse (other than tobacco)

- Concomitant drug treatment which raises endogenous nitric oxide levels such as
nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)

- History of symptomatic bradycardia or heart block